Organization
Amsterdam UMC, VU University Medical Center, Amsterdam, Netherlands
14 abstracts
Abstract
EPCORE NHL‑1 follicular lymphoma (FL) cycle (C) 1 optimization (OPT) cohort: Expanding the clinical utility of epcoritamab in relapsed or refractory (R/R) FL.Org: Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy, Erasmus MC Cancer Institute, University Medical Center, Department of Hematology, Rotterdam, Netherlands, Amsterdam UMC, VU University Medical Center, Amsterdam, Netherlands, Manchester Cancer Research Centre, The Christie NHS Foundation Trust, University of Manchester, Manchester, United Kingdom, Maria Skłodowska-Curie National Research Institute of Oncology, Kraków, Poland,
Abstract
Non-clinical evaluation of NT-112, an autologous T cell product engineered to express an HLA-C*08:02-restricted TCR targeting KRAS G12D and resistant to TGF-b inhibition.Org: Neogene Therapeutics, Santa Monica, CanSino Biologics, Amsterdam UMC, VU University Medical Center, Amsterdam, Netherlands, Netherlands Cancer Institute,
Abstract
The MARIANE-trial: Multicenter phase 1b/2 trial testing safety and efficacy of neoadjuvant intradermal ipilimumab and nivolumab in high-risk stage II melanoma.Org: The Netherlands Cancer Institute, Amsterdam UMC, VU University Medical Center, Amsterdam, Netherlands, Cancer Center Amsterdam, University Medical Center Groningen, Leiden University Medical Center,
Abstract
Adjuvant BRAF/MEK versus anti-PD-1 in BRAF-mutant melanoma: Propensity score–matched recurrence-free, distant metastasis-free, and overall survival analysis.Org: Leiden University Medical Center, Maastricht University Medical Centre, Zuyderland MC, The Netherlands Cancer Institute, University Medical Center of Utrecht,
Abstract
Genome-wide aneuploidy detected in circulating cell-free DNA of patients with metastatic urothelial cancer as a predictive biomarker of response to pembrolizumab.Org: Erasmus MC Cancer Institute, University Medical Center, Department of Hematology, Rotterdam, Netherlands, Erasmus University Rotterdam, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Amphia Hospital, Cancer Center Amsterdam,
Abstract
Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis.Org: Sorbonne University and Saint-Antoine Hospital, Mayo Clinic, Monash University School of Public Health and Preventive Medicine, Cardiff University School of Medicine, University of Pisa, Pisa, Italy,
Abstract
Nationwide implementation of best practices in pancreatic cancer care (PACAP-1): Stepped-wedge cluster randomized trial.Org: Amsterdam UMC, VU University Medical Center, Amsterdam, Netherlands, University of Amsterdam, Netherlands Comprehensive Cancer Organisation (IKNL), Department of Surgery, Brigham and Women's Hospital, Boston, MA, Department of Gastroenterology and Hepatology, Hokkaido University Hospital, Hokkaido, Japan,
Abstract
Artificial intelligence algorithm developed to predict immune checkpoint inhibitors efficacy in non–small-cell lung cancer.Org: University Hospital of North Norway, UiT The Arctic University of Norway, Brigham and Women's Hospital/Massachusetts General Hospital, Dana-Farber Cancer Institute, Lowe Center for Thoracic Oncology,
Abstract
A feasibility study of 177Lu-PSMA radioligand therapy alternated with radium-223 in patients with bone-metastatic, oligo-metastatic, hormone-sensitive prostate cancer after curative therapy: The DUET study.Org: Amsterdam UMC, VU University Medical Center, Amsterdam, Netherlands, location VUMC, Netherlands Cancer Institute,
Abstract
Infrastructure for rare cancer in the Netherlands: Towards a comprehensive platform for early detection and diagnosis of rare cancers (FORCE).Org: The Netherlands Cancer Institute, Amsterdam/UMC Utrecht ENETS Centre of Excellence, Department of Endocrine Oncology, University Medical Center Groningen, Máxima Medical Center,
Abstract
Patient-reported symptom monitoring linked to an alert algorithm: Effects on progression-free and overall survival in the SYMPRO-Lung trial.Org: Amsterdam UMC, VU University Medical Center, Amsterdam, Netherlands, Netherlands Comprehensive Cancer Organisation (IKNL), The Netherlands Cancer Institute, Radboud University Medical Center and Radboud Institute for Molecular Life Sciences,
Abstract
A prediction model for response to immune checkpoint inhibition in advanced melanoma.Org: University Medical Center Utrecht, Amsterdam UMC, VU University Medical Center, Amsterdam, Netherlands, VU University Medical Center, Isala Oncology Center, University Medical Center of Utrecht,
Abstract
Standardizing the strategy in glioblastoma trials to promote success in cell and gene therapy clinical development.Org: Parexel, Stockholm School of Economics Institute for Research, Stockholm, Sweden, Sweden, Parexel Intl, Durham Veteran Affairs Medical Center,
Abstract
Survival in patients with unresectable melanoma: To infinity and beyond?Org: University Medical Center of Utrecht, Amsterdam UMC, VU University Medical Center, Amsterdam, Netherlands, VU University Medical Center, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital/Netherlands Cancer Institute,